Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
15.80
-0.26 (-1.65%)
At close: Mar 6, 2026, 4:00 PM EST
15.80
+0.01 (0.03%)
After-hours: Mar 6, 2026, 5:40 PM EST

Corvus Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-15.08-62.29-27.03-41.31-43.24-6
Depreciation & Amortization
0.10.090.150.370.460.63
Stock-Based Compensation
4.5732.152.694.235.75
Other Adjustments
-22.735.434.399.815.07-37.07
Change in Receivables
0.04-0.050.56-0.08-0.51-
Changes in Accounts Payable
0.11.06-0.450.41-1.91.02
Changes in Accrued Expenses
1.51-0.25-3.580.47-0.520.71
Changes in Other Operating Activities
-0.61-2.41-0.130.62-0.30.19
Operating Cash Flow
-32.07-25.42-23.94-27.02-36.72-34.78
Capital Expenditures
-0.15--0.03-0.27-0.01-0.08
Sale of Property, Plant & Equipment
-0.01-0.02--
Purchases of Investments
-98.69-70.12-47.05-66.19-9.36-42.54
Proceeds from Sale of Investments
74.0842.6362.6243.1630.9287.39
Investing Cash Flow
-24.76-27.4815.54-23.2821.5644.77
Issuance of Common Stock
18.5549.037.86-62.161.31
Net Common Stock Issued (Repurchased)
18.5549.037.86-62.161.31
Financing Cash Flow
55.0249.037.86-62.161.31
Net Cash Flow
-1.81-3.88-0.54-50.34711.3
Free Cash Flow
-32.22-25.42-23.97-27.29-36.72-34.85
Free Cash Flow Per Share
-0.42-0.42-0.50-0.59-0.88-1.18
Levered Free Cash Flow
-14.13-63.81-31.07-39.72-45.52-3.53
Unlevered Free Cash Flow
-37.91-29.06-27.45-30.97-40.9-41.3
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q